Johnson & Johnson (NYSE:JNJ) wants an arbitrator to recind Schering-Plough's (SGP) lucrative marketing rights for arthritis treatment Remicade because SGP is being taken over by Merck (NYSE:MRK). JNJ -0.6% premarket. SGP -0.7%.
Johnson & Johnson (NYSE:JNJ) wants an arbitrator to recind Schering-Plough's (SGP) lucrative...
Recommended For You
More Trending News
About JNJ Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| JNJ | - | - |
| Johnson & Johnson | ||